Get the Stockscreener App
81.93
1.87%
-1.56
Pre-market:
82.49
0.56
+0.68%
Protagonist Therapeutics Inc stock is traded at $81.93, with a volume of 352.50K.
It is down -1.87% in the last 24 hours and up +2.09% over the past month.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
See More
Previous Close:
$83.49
Open:
$84.07
24h Volume:
352.50K
Relative Volume:
0.41
Market Cap:
$5.12B
Revenue:
$209.22M
Net Income/Loss:
$45.91M
P/E Ratio:
129.37
EPS:
0.6333
Net Cash Flow:
$63.71M
1W Performance:
+1.56%
1M Performance:
+2.09%
6M Performance:
+50.25%
1Y Performance:
+118.95%
1-Day Range:
$81.56
$84.72
1-Week Range:
$80.99
$85.05
52-Week Range:
$33.70
$96.54
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
(510) 474-0170
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
81.93 | 5.22B | 209.22M | 45.91M | 63.71M | 0.6333 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-12-25 | Initiated | Leerink Partners | Outperform |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-06-24 | Initiated | Goldman | Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Sep-24-24 | Initiated | TD Cowen | Buy |
| Sep-09-24 | Initiated | Truist | Buy |
| Oct-30-23 | Initiated | CapitalOne | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-21 | Initiated | JMP Securities | Mkt Outperform |
| May-24-21 | Initiated | Northland Capital | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Dec-16-20 | Initiated | Piper Sandler | Overweight |
| Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Initiated | Jefferies | Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| May-09-19 | Upgrade | Stifel | Hold → Buy |
| Dec-06-18 | Initiated | Nomura | Buy |
| Jan-29-18 | Initiated | Stifel | Buy |
| Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
Protagonist Therapeutics (PTGX) to Release Earnings on Friday - MarketBeat
H.C. Wainwright Raises Protagonist Therapeutics, Inc. (PTGX) Target to $117, Reiterates Buy - Finviz
10 Best Long Term Healthcare Stocks to Buy - Insider Monkey
Protagonist Therapeutics director sells $1.67 million in shares By Investing.com - Investing.com Canada
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Director Sells 20,000 Shares of Stock - MarketBeat
Assessing Protagonist Therapeutics (PTGX) Valuation After Rusfertide NDA Filing And Rising Analyst Optimism - simplywall.st
Precision Trading with Protagonist Therapeutics Inc. (PTGX) Risk Zones - Stock Traders Daily
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 - El Paso Times
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: A Biotech Gem with 22% Upside Potential - DirectorsTalk Interviews
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress - The Asheville Citizen Times
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $118.00 at Jefferies Financial Group - MarketBeat
Jefferies Raises Price Target for PTGX to $118, Maintains 'Buy' Rating | PTGX Stock News - GuruFocus
ClearBridge small-cap growth trims Duolingo, Biohaven, QLYS; adds PTGX, SSD, BETA, DYN in Q4 - MSN
Equities Analysts Set Expectations for PTGX FY2030 Earnings - MarketBeat
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes - AOL.com
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Unicycive Therapeutics (UNCY) - The Globe and Mail
PTGX: HC Wainwright & Co. Raises Price Target and Maintains Buy Rating | PTGX Stock News - GuruFocus
Breaking Down Protagonist Therapeutics: 8 Analysts Share Their Views - Benzinga
Protagonist Therapeutics stock price target raised to $117 from $80 at H.C. Wainwright - Investing.com Canada
Protagonist Therapeutics CMO Sells Shares in Major Transaction - Intellectia AI
Protagonist Therapeutics, Inc. $PTGX Shares Sold by Great Lakes Advisors LLC - MarketBeat
Protagonist Therapeutics: Assessing The 2026 Upside For Icotrokinra And Rusfertide - Seeking Alpha
Protagonist Therapeutics CEO Patel sells $4m in shares By Investing.com - Investing.com South Africa
Ali Asif, CFO of protagonist, sells $3.8m in PTGX stock - Investing.com Canada
PTGX SEC FilingsProtagonist Ther 10-K, 10-Q, 8-K Forms - Stock Titan
Protagonist Therapeutics CEO Patel sells $4m in shares - Investing.com
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Insider Sells 5,000 Shares of Stock - MarketBeat
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Insider Sells 13,151 Shares of Stock - MarketBeat
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells 24,890 Shares of Stock - MarketBeat
Protagonist Therapeutics chief medical officer sells $1.9m in shares By Investing.com - Investing.com Canada
JPMorgan reiterates Overweight rating on Protagonist Therapeutics stock By Investing.com - Investing.com Canada
VIX Spike: Can Protagonist Therapeutics Inc weather a recessionStop Loss & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Universal Beteiligungs und Servicegesellschaft mbH Raises Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) CFO Asif Ali Sells 46,203 Shares - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Technical Reactions to PTGX Trends in Macro Strategies - Stock Traders Daily
Have Insiders Sold Protagonist Therapeutics Shares Recently? - Sahm
Earnings Risk: Will Protagonist Therapeutics Inc benefit from AI trendsAnalyst Downgrade & Daily Market Momentum Tracking - baoquankhu1.vn
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - citizen-times.com
Analysts Are Bullish on These Healthcare Stocks: Protagonist Therapeutics (PTGX), CG Oncology, Inc. (CGON) - The Globe and Mail
Protagonist therapeutics CEO Patel sells $2.84 million in shares By Investing.com - Investing.com India
Protagonist therapeutics CMO Molina sells $784k in shares By Investing.com - Investing.com Canada
Asif Ali Sells 8,588 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Insider Arturo Md Molina Sells 9,514 Shares - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $2,840,446.24 in Stock - MarketBeat
Protagonist therapeutics CEO Patel sells $2.84 million in shares - Investing.com
Protagonist Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Strong Buy Ratings Signal Potential 17% Upside - DirectorsTalk Interviews
US Market Wrap: Is Protagonist Therapeutics Inc trading at a discount2025 Bull vs Bear & Free Community Consensus Stock Picks - baoquankhu1.vn
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):